The tumor microenvironment plays a critical role in determining the fate of tumor cells. We have previously reported that adhesion of human myeloma and leukemia cell lines to the extracellular matrix protein, fibronectin, confers a multidrugresistant phenotype. Mechanisms associated with this cell adhesion-mediated drug resistance are drug-type specific. In the present study, we examined the influence of bone marrow stromal cells (BMSCs) on myeloma cell response to the topoisomerase II inhibitor, mitoxantrone. Apoptosis was inhibited by more than 50% when cells were adhered to BMSCs as compared to myeloma cells maintained in suspension. To investigate the mechanisms contributing to the resistance of myeloma cells in contact with BMSCs, we examined the protective effects of BMSCs under four separate conditions:
Introduction
Despite recent advances in the treatment of multiple myeloma, this disease still remains incurable, largely because of the emergence of drug-resistant tumor cells. A large number of studies have focused on mechanisms of acquired drug resistance following prolonged treatment with cytotoxic drugs.
1,2 However, there is increasing evidence supporting the role of environmental factors in the initial escape of the tumor cells from cytotoxic agents. [3] [4] [5] [6] The bone marrow (BM) microenvironment includes both soluble factors, such as cytokines and growth factors, and physical interactions with stromal cells and extracellular matrix (ECM) molecules. The ECM has been well documented to promote the survival of both solid tumors and hematopoietic cells; however, less is known about the influence of the adjacent, nontransformed stromal cells on the survival of myeloma tumors.
According to Garrido et al 7 direct contact of acute myelogenous leukemia cells from untreated patients with the fibroblastoid cell line HS-5 conferred protection from spontaneous apoptosis, and reduced the cytotoxicity of cytosine arabinoside (Ara-C) or daunomycin. In a second study, Mudry et al 8 demonstrated enhanced survival of B-lineage acute lymphoblastic leukemia cell lines cultured in direct contact with bone marrow stromal cells (BMSCs), but not in the presence of conditioned medium from BMSCs, following exposure to Ara-C or etoposide. However, this effect was not seen in the Jurkat T-cell line, suggesting a lineage-specific mechanism. Finally, Cheung and Van Ness 9 reported that direct contact with BM stroma protected the interleukin-6 (IL-6)-dependent cell line ANBL6 from dexamethasone-induced, but not from doxorubicin-induced cell death. 9 These studies suggest that further investigation is warranted into the role of the BM stromal cells in myeloma cell growth and survival.
BMSCs express a large number of adhesive molecules involved in both cell-cell and cell-ECM interactions. In addition, the BM stroma is a rich source of cytokines, hormones, and growth factors, further adding to the complexity of the environment. Elevated levels of IL-6, vascular endothelial growth factor (VEGF), and basic fibroblast-growth factor (bFGF) have been described in the peripheral blood and BM of myeloma patients. Furthermore, cytokine levels appear to correlate with the severity and progression of disease and have been suggested to contribute to the emergence of drug-resistant disease. [10] [11] [12] [13] [14] [15] In recent years, a number of studies have demonstrated the importance of cell adhesion to the ECM component, fibronectin, (FN), as a mechanism of cell survival. [15] [16] [17] [18] [19] [20] Previous work from our laboratory has defined a microenvironmentally regulated resistance to programmed cell death in response to both chemotherapeutic drugs and physiological stimuli. [18] [19] [20] This phenomenon, termed cell adhesion-mediated drug resistance (CAM-DR), was mediated via b1-integrin ligation, and has been shown to confer resistance to programmed cell death induced by both cytotoxic drugs and death receptors. In the present study, we investigated the role of direct cell contact between myeloma cells and BMSCs, and the contribution of soluble factors produced by this cell-cell interaction, in preventing drug-induced apoptosis. We report that in myeloma-BMSCs interactions, both direct physical contact and soluble factors generated by cell-cell interaction contribute to resistance to mitoxantrone; however, the mechanisms for each are distinct.
Materials and methods

Reagents, antibodies, and drugs
Anti-human VEGF, anti-bFGF, and anti-IL-6 antibodies and goat IgG were purchased from R&D Systems (Minneapolis, MN, USA). PE-conjugated anti-human CD38 and PE-conjugated mouse IgG1 antibodies were obtained from Becton Dickinson (San Jose, CA, USA). Bromodeoxyuridine (BrdU) and propidium iodide (PI) were from Sigma (St Louis, MO, USA); anti-BrdU FITC-conjugated antibody was from DAKO (Carpinteria, CA, USA). Mitoxantrone was purchased from Sigma (St Louis, MO, USA).
Cell cultures
RPMI 8226 and NCI H929 myeloma cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA) and were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ ml streptomycin, and 1% L-glutamine (all from Gibco BRL, Grand Island, NY, USA). H929 cells were also supplemented with 0.05 mM 2-mercaptoethanol. BMSCs cultures were established from BM aspirates of healthy donors after suitable informed consent and according to the method of Lagneaux et al 21 as modified by Dankbar et al. 22 Briefly, mononuclear cells obtained after Ficoll-Hypaque density centrifugation were suspended in a-minimal essential medium (a-MEM, GibcoBRL, Grand Island, NY, USA) supplemented with 10% FBS and antibiotics at a concentration of 1 Â 10 6 cells/ml. Cells were fed after four days by adding one-half volume of complete medium, and then at weekly intervals by complete replacement of the medium until development of a confluent monolayer. BMSCs were used within 4-6 weeks of establishment. BMSCs prepared by this protocol were reported to be primarily fibroblasts (CD54-positive) with a low proportion of macrophages (CD68-positive). No expression of the endothelial markers CD31 and thrombomodulin was detected. 22 
RNAse protection assay (RPA)
Expression of Bcl-2 family members mRNA was detected by RNase protection assay as previously described. 23 RPA was performed using PharMingen RiboQuant kit (San Diego, CA, USA) according to the manufacturer's protocol using a multitemplate probe, which includes the Bcl-2 family members bclw, bclx L/S, bfl1, bad, bik, bak, bax, bcl-2, and mcl-1 as well as the housekeeping genes L32 and GAPDH as standards. Quantitation was performed on a Storm phosphor imager using ImageQuaNT software (Molecular Dynamics, Inc., Sunnyvale, CA, USA).
Cell cycle distribution
Myeloma cells (1.5 Â 10 6 cells) either adhered to BMSCs, separated from BMSCs by Transwell (TW) inserts, or kept in suspension were treated for 40 min with 30 mg/ml BrdU, collected and fixed in ice-cold 66% ethanol. Cells were stained with anti-BrdU and PI as previously described 19 and analyzed by flow cytometry.
Western blotting
Cells were collected at time points indicated, washed twice with ice-cold PBS, and lysed in RIPA buffer. 19 Equal protein was separated on a 12% SDS-PAGE, transferred to PVDF membrane and blocked with 5% milk in TBS/T. The membrane was then probed with polyclonal p27 antiserum (Santa Cruz Biotech), washed with TBS/T and incubated with HRP-conjugated antirabbit secondary antibody for 1h. Specific band was developed by chemiluminescence (Amersham). To confirm equal loading, membrane was reprobed with monoclonal b-actin antibody (Sigma).
Proliferation assay
BMSCs were irradiated by 2500 rad and then seeded at 10 000 cells/well in 96-well plates. RPMI 8226 or H929 myeloma cells were added to the BMSCs monolayer and plates were incubated for 24 or 48 h. Cultures were pulsed with [ 3 H] thymidine for 16 h prior to harvesting and scintillation counting of incorporated radioisotope.
Apoptosis detection
Two different regimens of drug exposure were used: (1) continuous treatment with mitoxantrone for 24 h and, (2) pulse treatment for 1 h followed by washing and additional 23 h incubation in complete culture medium (a-MEM with 10% FBS and antibiotics). For comprehensive evaluation of apoptosis, we used two different methods: Annexin-V binding assay for detection of early apoptosis, and TUNEL assay allowing detection of late apoptotic events. Mitoxantrone dose and duration of exposure were optimized for the analysis method.
TUNEL assay: Cells were collected, washed with PBS, and stained with PE-conjugated anti-CD38 antibody (BD-Pharmingen). Cells were then fixed in 1% paraformaldehyde in PBS for 15 min on ice, washed two times with ice-cold PBS, resuspended in 70% cold ethanol, and kept at least 2 h at À201C. TUNEL staining was performed using the Apo-BrdU Kit (PharMingen, San Diego, CA, USA) according to the manufacturer's protocol. Briefly, cells were permeabilized and labeled with BrdUTP using terminal deoxytransferase for 1 h at 371C, followed by incubation with FITC-conjugated anti-BrdUTP antibody. Two-color flow cytometry was used to identify apoptotic cells in the CD38-positive myeloma cells population using CELLQuest software. CMXRos staining: To detect the involvement of mitochondrial perturbation, myeloma cells were cultured on 0.2 mm TW inserts (0.4 Â 10 6 cells per insert) or in suspension for 24 h, followed by 24 h drug treatment. CMXRos (200 nM) (Molecular Probes, Eugene, OR, USA) was added to the culture for the last 30 min, washed twice with PBS, resuspended in PBS and analyzed by flow cytometry.
Annexin-V staining:
Preparation of conditioned medium
BMSCs were grown in six-well plates in aMEM with 10% FBS. When cultures were 80-90% confluent, the medium was exchanged for aMEM with 1% FBS and conditioned medium was collected following 48 h incubation. Conditioned medium was filtered on a 0.22 mM filter, and used for experiments immediately after preparation. Myeloma cells were incubated for 24 h in complete medium in the presence of 0, 25, 50, or 75% conditioned medium from BMSCs followed by treatment for an additional 24 h with mitoxantrone. Apoptosis was measured by Annexin-V binding and TUNEL assays as described above.
Statistical analysis
Results obtained from triplicates or quadruplicates are presented as mean 7s.d. Statistical significance of the differences between experimental conditions was calculated by Student's t-test.
Results
We have previously demonstrated that adhesion of myeloma and leukemia cells to the ECM component FN significantly increased cellular resistance to a variety of cytotoxic drugs including topoisomerase II inhibitors. 18, 19, 24 In the present study, we investigated whether live BMSCs would influence the response of myeloma cells to the topoisomerase II inhibitor mitoxantrone. Although mitoxantrone is used less frequently than doxorubicin as an antimyeloma drug, it has been extensively characterized as a classic topoisomerase II inhibitor, and does not possess the fluorescent features of doxorubicin. [25] [26] [27] Since the BM microenvironment is a complex system, with potential contributions of both physical adhesion and soluble factors, we used four experimental conditions to differentiate these interactions: (1) myeloma cells cocultured with BMSCs, (2) myeloma cells adhered to BMSCs, (3) myeloma cells in TW culture (nondirect contact) with BMSCs, or (4) myeloma cells suspended in medium conditioned in the prior presence of BMSCs (BMSCs CM).
Coculturing myeloma cells with BMSCs inhibits drug-induced apoptosis
Initially we examined the cytotoxicity of the mitoxantrone on H929 and RPMI 8226 human myeloma cells cocultured with BMSCs established from normal healthy donors. Myeloma cells were cultured for 24 h with a previously established BMSC monolayer, followed by drug exposure for an additional 24 h. As shown in Figure 1a , treatment of H929 cells with 1 mM or 2 mM mitoxantrone for 24 h induced 2176 and 4972% cell death, respectively, in cells maintained in suspension, compared to 1273 and 2878% of myeloma cells cocultured with BMSCs (Po0.05). Similar results were obtained for RPMI 8226 Role of the bone marrow stroma in drug resistance of myeloma cells Y Nefedova et al myeloma cells (Figure 1b) . Thus, apoptosis in H929 and RPMI 8226 cells was significantly reduced in the presence of BMSCs compared to myeloma cells exposed to mitoxantrone in suspension.
A drug-accumulation assay was performed to determine whether these differences were because of reduced drug uptake by myeloma cells cultured in the presence of BMSCs. H929 cells in suspension or in culture with BMSCs were exposed to 14 Cmitoxantrone, and drug uptake analyzed by scintillation counting. We found no significant difference in total intracellular 14 
C-mitoxantrone in
H929 cells in suspension compared to H929 cells cultured in the presence of BMSCs (3417112 cpm in suspension cells vs 282769 cpm in BMSCs adhered cells, P ¼ 0.42), indicating that intracellular drug accumulation in myeloma cells does not account for the reduced response of myeloma cells in the presence of BMSCs.
Direct physical contact of BMSCs with myeloma cells contributes to CAM-DR
We next investigated whether a stable physical adhesion of the myeloma cells to the BMSCs contributed to the protection of cells from mitoxantrone treatment. To measure apoptosis in only those myeloma cells stably adhered to BMSCs, 1.0 Â 10 6 per well of H929 or RPMI 8226 cells were added to a confluent monolayer of BMSCs in six-well plates. After 2 h incubation, non-adherent cells were removed by washing 3 Â with serumfree media. Preliminary experiments demonstrated that approximately 70% of myeloma cells adhered to BMSCs under these conditions (data not shown). Adhered cells were exposed to mitoxantrone for 1 h followed by 23 h incubation in drug-free medium. Myeloma cells were identified by staining with CD38, and myeloma cell death was measured by TUNEL assay with gating on CD38-positive cells. As shown in Figure 2 , adhesion to BMSCs reduced drug cytotoxicity by 2.5-fold compared to cells maintained in suspension (87.375.2% cell death in suspension vs 37.5718.6% in adhered cells, P ¼ 0.037). This effect was independent of the cell-cell contact time prior to the drug exposure, as similar results were obtained when multiple myeloma (MM) cells were adhered to BMSCs for 24 h prior to drug exposure.
Role of soluble factors in protection of myeloma cells from drug-induced apoptosis
Soluble factors produced by myeloma cells and adjacent stromal cells have been implicated in the pathogenesis and progression of multiple myeloma. To examine the contribution of soluble factors independent of physical cell contact, we used TW inserts to separate H929 or 8226 myeloma cells and BMSCs. As shown in Figure 3a , mitoxantrone-induced H929 cell death was reduced by two-fold in the presence of BMSCs from a mean of 49+1.5% in suspension cells to 23.7+5.1% (Po0.05). Similar results were obtained for 8226 cells exposed to mitoxantrone. However, when we exposed myeloma cells to mitoxantrone in the presence or absence of conditioned medium prepared from BMSCs, we found no differences in myeloma cell death (Figure 3b) . These data suggest a dynamic interaction between the myeloma cells and BMSCs, where myeloma cells induce the production of soluble factors by the stromal cells, or BMSCs stimulate the production of soluble factors by the myeloma cells, which, in turn, confers resistance to programmed cell death. To test this hypothesis, we examined mitoxantrone-induced cell death in H929 myeloma cells preincubated with BMSCs in TW culture for 24 h prior to drug exposure compared to cell death induced in myeloma cells placed in TW culture with BMSCs immediately prior to drug treatment. As shown in Figure 3c , the presence of BMSCs during drug exposure protected the H929 myeloma cells from mitoxantrone cytotoxicity. Importantly, this effect became more prominent after preincubation of BMSCs with myeloma cells for 24 h before drug treatment, suggesting the accumulation of protective factors in the culture medium. Again, similar data were obtained with the 8226 myeloma cell line.
It has been reported that patients with MM frequently have elevated levels of VEGF, bFGF, and IL-6 in the BM plasma. 12, 22, 28, 29 These soluble factors are thought to be produced by both the myeloma cells themselves, as well as by accessory cells, including BMSCs. 30, 31 To identify factors that may be involved in the BMSC-mediated protection of myeloma cells from mitoxantrone-induced apoptosis, H929 cells were incubated in TW inserts separated from BMSCs in the presence of anti-VEGF, anti-bFGF, or anti-IL-6 blocking antibodies for 24 h followed by treatment for another 24 h with mitoxantrone. As shown in Figure 3d , anti-VEGF, anti-bFGF, and anti-IL-6 blocking antibodies did not influence the myeloma response to mitoxantrone, suggesting these factors are not individually responsible for BMSC-mediated drug resistance.
Coculturing and adhesion of myeloma cells to BMSCs are associated with growth arrest, while nondirect contact with BMSCs stimulates proliferation
Since the activity of some drugs, including topoisomerase II inhibitors, may be affected by the cell cycle status, we examined the influence of BMSC-MM cell interaction on myeloma cell cycle kinetics. Using [ 3 H]thymidine incorporation, we found a time-dependent inhibition of DNA synthesis in myeloma cells Po0.05 at all points. To identify the phase of cell cycle arrest, we analyzed BrdU incorporation and DNA content. As shown in Figure 4c , adhesion of H929 cells to BMSCs was associated with an accumulation of cells in the G1 phase. This adhesionmediated growth arrest was more significant in RPMI 8226 cells (Figure 4d ). Previous reports have demonstrated an accumulation of the cyclin-dependent kinase inhibitor, p27, which correlated with adhesion of myeloma cells to FN, and contributed to drug resistance. 19 We therefore examined p27 expression in H929 cells adhered to BMSCs compared to cells maintained in suspension (Figure 4e ). No differences were identified in protein expression following 48 h adhesion, suggesting that the mechanism(s) of resistance in BMSC adhered cells is distinct from that identified when cells are adhered to the ECM component FN.
To determine the effects of soluble factors in cell cycle progression, myeloma cells were placed in TW culture with a BMSC monolayer in the lower chamber. In contrast to adherent cells, myeloma cells in TW culture (nondirect contact) with BMSCs demonstrated an increase in proliferation (Figure 4f) . At 24 h, H929 cells in nondirect contact with BMSCs demonstrated a 2.0-fold increase in the S phase, with transition to a 1.9-fold increase in G2 at 48 h (Po0.05). This is not a cell cycle arrest, but rather a synchronized transition, as the proportion of cells in G2 is decreased more than two fold at 72 h. Similar data were obtained for 8226 cells (data not shown).
A mitochondria-dependent apoptotic pathway is activated following incubation of myeloma cells in nondirect contact with BMSCs
To determine if the protection from drug cytotoxicity occurs at the level of the mitochondria, we examined the differences in mitochondrial potential following mitoxantrone treatment. As shown in Figure 5a , mitoxantrone exposure perturbed mitochondrial function by up to 6273.4% in myeloma cells in suspension culture compared to 46711.6% of cells cultured on TW inserts in nondirect contact with BMSCs (P ¼ 0.002). 6 cells/per well) were incubated an additional 46 h followed by pulsing with BrdU for 40 min and staining with anti-BrdU-FITC for detection of S-phase cells detection and PI for cell cycle distribution. (e) H929 cells were adhered to BMSCs (A) or maintained in suspension (S) for 48 h. After that time, myeloma cells were collected, washed with PBS, and cell lysates analyzed by Western blot as previously described. 19 (f) H929 cells (0.8 Â 10 6 cells/per TW) were kept in suspension (control) for 48 h or incubated on TW in the presence of BMSCs for 24 or 48 h. After pulsing with BrdU for 40 min, myeloma cells were collected and fixed followed by anti-BrdU-FITC/PI staining.
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Mitochondrial permeability is regulated by the relative expression of proapoptotic and antiapoptotic Bcl-2 family proteins. Therefore, we utilized RNase protection analysis to examine the effect of BMSC-myeloma-derived soluble factors on the mRNA expression levels of Bcl family members. No significant differences were detected in the expression of the antiapoptotic genes bcl-2, bcl-xL, and mcl-1 in H929 cells cultured in nondirect contact with BMSCs compared to H929 cells kept in suspension (Figure 5b ). Although this does not entirely rule out the possibility that Bcl-2 family members may contribute to BMSC-mediated protection of myeloma cells, further studies are warranted to define the role of these proteins in this system.
Discussion
The tumor microenvironment has previously been demonstrated to alter the sensitivity of tumor cells to cytotoxic drugs and radiation. 18, 19, 24, [32] [33] [34] MM is a latent disease of the BM, where the tumor cell phenotype likely reflects a combination of multiple interactions including cell-cell, cell-ECM, and cellgrowth factor. In this study, we demonstrate that the presence of BMSCs during treatment of H929 or RPMI 8226 cells with mitoxantrone significantly reduces apoptosis in myeloma cell lines. BMSCs influence myeloma cell survival through several mechanisms including direct cell-cell contact and the effects of soluble factors. To determine the relative contribution of soluble factors vs direct physical contact, we examined the interaction of myeloma cells with normal BMSCs under four separate conditions: (1) direct cell contact; (2) BMSCs conditioned medium; (3) medium conditioned by coculturing myeloma cells and BMSCs with direct contact; and (4) medium conditioned by coculturing myeloma cells and BMSCs without direct physical contact. Differentiation of the effects of physical contact vs soluble factors demonstrated a much greater protective effect when the myeloma cells were physically adhered to the BMSCs, suggesting that cell-cell contact and soluble factors may act in an additive fashion. The specific receptors involved in myeloma cell-BMSC interactions have not been fully identified; however, several potential candidates have been described. 31, 35 ECM and stromal cell surface ligands known to participate in tumor cell survival include: VCAM-1 and FN, which are ligands for VLA-4; ICAM-1 and ICAM-2, which are coreceptors for LFA-1; collagen I and laminin, which bind to VLA-2 and 3; and hyaluronic acid, which is a ligand for CD44. However, the relative contribution of these ligands in our system has not been fully defined. Our studies suggest that one of the possible mechanisms contributing to BMSCs-mediated protection could be related to the significant growth arrest of the myeloma cells following adhesion to BMSCs. The accumulation of myeloma cells in the G 0 /G 1 phase of the cell cycle after adhesion to BMSCs is consistent with previously reported similar findings in cells adhered to FN 19 and may represent an important characteristic of the antiapoptotic phenotype.
The protective interaction between the myeloma cells and BMSCs is not limited to adhesion. Using cell cultures separated by TW membrane, we demonstrated a significant contribution of soluble factors to the protection of myeloma cells from druginduced apoptosis. However, this effect was not reproduced with BMSCs conditioned medium, indicating that nonactivated stromal cells do not produce factors protecting myeloma cells from drug-induced apoptosis. We propose that myeloma cellderived factor(s) are required to activate the BMSCs, which then produce factor(s) that protect myeloma cells during initial drug exposure. If such a dynamic interaction between myeloma cells and BMSCs exists, then preincubation of the two cell types should significantly increase the degree of protection of myeloma cells in a time-dependent manner. Indeed, we demonstrated a significant decrease in cell death of myeloma cells preincubated with BMSCs. Further definition of the factors involved may provide an opportunity to enhance the initial response of myeloma patients, and reduce the incidence of acquired drug resistance.
The nature of the soluble factors contributing to BMSCsmediated protection, as well as the mechanisms of activity, remain under investigation. Recently, myeloma cell lines and malignant plasma cells from patients with MM were shown to secrete VEGF, which in turn stimulated proliferation of the myeloma cells. 22, 36, 37 VEGF exerts its effects through interaction with receptors, mainly with FLT-1 and FLK1/KDR. However, most myeloma cell lines and primary myeloma cells fail to express these VEGF receptors. 22, 36 In contrast, these receptors are abundantly expressed by BMSCs, suggesting that VEGF may affect tumor cells in paracrine fashion through stimulation of BM stroma. Data demonstrating increased secretion of IL-6 by BMSCs after stimulation with VEGF and higher levels of VEGF production by myeloma cells after stimulation with IL-6 support this hypothesis. 22 Although VEGF, bFGF, and IL-6 have been shown to be active in myeloma cell proliferation and resistance to dexamethasone, we did not find evidence of these growth Mitochondria-dependent pathway is activated following incubation of H929 cells in nondirect contact with BMSCs. (a) H929 myeloma cells were incubated in TW culture with BMSCs in the lower chamber for 24 h followed by 24 h mitoxantrone treatment. Mitochondrial potential was measured by flow cytometry using the mitochondrial permeable dye, CMXros. Data shown are the mean of two independent experiments done in triplicate. (b) Autoradiograph of mRNA expression analyzed by RPA.
Role of the bone marrow stroma in drug resistance of myeloma cells Y Nefedova et al factors contributing to BMSCs conferred resistance to the topoisomerase II inhibitor mitoxantrone. Additional studies are needed to clarify the nature of the BMSC-associated soluble factors involved in the enhanced survival of myeloma cells following mitoxantrone exposure. Owing to the large number of potential candidate cytokines, and the complex interactions they may involve, a more comprehensive approach such as proteomics or genomics will be required to define this system. The fact that BMSC-derived soluble factors protect myeloma cells from cell death raises the question of alterations in the apoptotic pathway. The observed differences in the mitochondrial membrane potential of cells protected by BMSCs soluble factors compared to untreated cells suggested the protective mechanism may occur at or above the level of the mitochondria, thereby implicating Bcl family members. The Bcl family members most frequently associated with enhanced survival in myeloma cells include bcl-2, bcl-xL, and mcl-1. However, analysis of mRNA expression did not demonstrate any significant differences in these genes. Additional studies are warranted to conclusively identify the role of the mitochondria in BMSC-mediated drug resistance.
Our data clearly demonstrate an important role of BMSCs in therapeutic apoptosis of myeloma cells. It appears that interaction between BMSCs and myeloma cells is taking place by two distinct mechanisms. The first mechanism involves direct cell contact between adjacent cell types, resulting in partial inhibition of myeloma cell proliferation and accumulation in G 0 /G 1 . This may provide the first line of protection against druginduced apoptosis. Concurrently, interactions between myeloma cells and BMSCs result in the production of soluble factors that inhibit apoptosis of myeloma cells, mostly likely at the level of the mitochondria. This work has demonstrated the complex interactions between BMSCs and MM cells that contribute to the de novo drug resistance of MM cells, and has provided a model for further investigation of individual mechanisms. The development of therapeutic strategies designed to overcome initial drug resistance should take into account these different mechanisms.
